Dipexium Pharmaceuticals Inc. is still sorting through data from a pair of identical phase III trials, but top-line findings in mild infections of diabetic foot ulcers with the company's lead – and only – product did nothing to encourage investors, and shares (NASDAQ:DPRX) tumbled 78 percent, or $9.95, to close Tuesday at $2.80.